FDA OKs Ibalizumab, a Sterile Biologic for HIV
// // // // // // // // // // // // // // // // // // // // //
WuXi PharmaTech and TaiMed Biologics announced that the FDA has approved the first batch of the ibalizumab drug substance and sterile drug product, manufactured at WuXi’s biologics facilities, for ongoing treatment of patients under investigator-sponsored INDs. Read more…FULL STORY
FDA OKs Ibalizumab, a Sterile Biologic for HIV
// // // // // // // // // // // // // // // // // // // // //
Ibalizumab is a humanized monoclonal antibody and a member of an emerging class of HIV therapies known as viral-entry inhibitors. It is being developed by TaiMed Biologics for the treatment of HIV/AIDS infection.
Filed under: ANTIBODIES, Monoclonal antibody Tagged: Ibalizumab, TaiMed Biologics, WuXi PharmaTech
